John Orloff

Dr. Orloff is Venture Partner at Agent Capital, a healthcare venture capital firm based in Waltham, MA. Prior to Agent Capital, he served as EVP and Global Head of R&D for Alexion, where his leadership in expanding the development pipeline from three to 30 programs supported the recent $39 billion acquisition of Alexion by AstraZeneca. Prior to Alexion, Dr. Orloff was Global Head of R&D and Chief Scientific Officer at Baxalta, and has also held executive leadership roles with Novelion, Baxter International, Merck Serono, Novartis and Merck Research Laboratories.

Before entering the biopharmaceutical industry, he was a faculty member at the Yale University School of Medicine. Dr. Orloff received an undergraduate degree in chemistry from Dartmouth College, earned his medical degree from the University of Vermont, College of Medicine and completed a fellowship in endocrinology and metabolism at Yale University School of Medicine.